波士顿 - 目前市值为877万美元、股价为6.96美元的微型生物科技公司Sensei Biotherapeutics, Inc. (NASDAQ: SNSE )将在即将于柏林举行的欧洲肿瘤内科学会大会上展示其solnerstotug单药及与Regeneron的PD-1抑制剂Libtayo (cemiplimab)联合用药的1/2期临床试验数据。根据 InvestingPro ...

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and ...

Ordering dead drops and paying off your debts in Schedule 1 will have you befriending your suppliers in no time. Once you've reached a loyal relationship ...

Furthermore, additional regulators of thymus homing in the steady state and following BMT have been identified, including PSGL-1, the ligand for P-Selectin (80, 92), and lymphotoxin beta receptor ...